Breast Cancer Index Identifies Patients Who Will Benefit From Extended Endocrine Therapy, Data Shows

Breast Cancer Index Identifies Patients Who Will Benefit From Extended Endocrine Therapy, Data Shows
Biotheranostics' Breast Cancer Index can help distinguish which breast cancer patients will derive a benefit from prolonged endocrine therapy — allowing those who don't to stop treatment and avoid its unpleasant side effects, new data suggests. The findings were shared at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, held recently in Chicago, in a presentation titled, "Trans-aTTom: Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen—To offer more? (aTTom) trial." Endocrine therapy starves tumors of the hormones, primarily estrogen, that drive cancer cell growth. For people with hormone receptor (HR)-positive breast cancer, it can be lifesaving. However, endocrine therapy also can cause a number of unpleasant side effects, including osteoporosis, joint pain, blood clots, and endometrial cancer. This has led to a dilemma over how long endocrine therapy should be given — for five or 10 years? The Breast Cancer Index (BCI), a test that measures gene expression in the tumor, is intended to solve this problem by identifying those patients who will benefit from the additional five years of treatment. That would allow clini
Subscribe or to access all post and page content.

One comment

  1. Hey this is somewhat of off topic but I was wondering if blogs use WYSIWYG editors or if you
    have to manually code with HTML. I’m starting a blog soon but have no coding experience so I wanted to get advice
    from someone with experience. Any help would be enormously
    appreciated!

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.